Neurology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Evaluate Sex Differences in Multiple Sclerosis Spectrum of Demyelinating Disorders

   Rochester, Minn.

   The purposes of this study are to explore the association between female sex, reproductive history and clinical phenotypic variability in multiple sclerosis (MS), to explore the association between female sex, reproductive history and radiologic phenotypic variability in MS, and to explore the association between female sex, genetic and environmental interactions in MS.

    

2. A Study of Pyridostigmine in Postural Tachycardia Syndrome

   Rochester, Minn.

   This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

3. A Study of Nervous System Involvement of Coccidioidomycosis at Mayo Clinic Hospital in Arizona

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis. 

4. A Study to Evaluate Veliparib, Radiation Therapy, and Temozolomide in Treating Participants with Newly Diagnosed Malignant Glioma without H3 K27M or BRAFV600 Mutations

   Rochester, Minn.

   The purpose of this study is to evaluate how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.

5. A Study to Evaluate Pembrolizumab with Standard Therapy to Treat Newly-diagnosed Glioblastoma

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Drugs used in the chemotherapy, such as pembrolizumab and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy may kill tumor cells.

6. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases

   Rochester, Minn.

   The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2).

   In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.

7. Focal and Multifocal Chronic Inflammatory Demyelinating Polyradiculoneuropathies

   Rochester, Minn.

   The purpose of this study is to characterize the focal forms of CIDP (which we will term chronic inflammatory demyelinating mononeuropathy, or CIDM).

8. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

9. A Study to Examine the Natural History of Infants and Children with SCN1A-positive Dravet Syndrome

   Rochester, Minn.

   The purpose of this study is to characterize the phenotype of SCN1A-positive Dravet Syndrome in subjects aged 6 to 60 months, inclusive.

10. A Study to Assess Neuroinflammation in Epileptic Tissue Immediately Prior to Surgical Resection Using Intraoperative Brain Microdialysis

    Rochester, Minn.

    The purpose of this study is to measure the space and time characteristics of inflammatory mediator release in response to induced epileptiform activity in ASD-resistant patients.